BioMarin Pharmaceuticals
BMRN
BMRN
466 hedge funds and large institutions have $14.7B invested in BioMarin Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 81 funds opening new positions, 181 increasing their positions, 133 reducing their positions, and 45 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
466
Holders Change
+31
Holders Change %
+7.13%
% of All Funds
9.2%
Holding in Top 10
10
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+11.11%
% of All Funds
0.2%
New
81
Increased
181
Reduced
133
Closed
45
Calls
$156M
Puts
$147M
Net Calls
+$8.14M
Net Calls Change
+$38.8M
Top Buyers
| 1 |
Dodge & Cox
San Francisco,
California
|
+$371M |
| 2 |
JPMorgan Chase & Co
New York
|
+$110M |
| 3 |
Primecap Management
Pasadena,
California
|
+$98.7M |
| 4 |
Westfield Capital Management
Boston,
Massachusetts
|
+$43.8M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$40.4M |
Top Sellers
| 1 |
Sands Capital Management
Arlington,
Virginia
|
-$375M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$138M |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$135M |
| 4 |
Viking Global Investors
Stamford,
Connecticut
|
-$121M |
| 5 |
Jennison Associates
New York
|
-$109M |
